CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Halobetasol propionate and tazarotene

Last Updated: July 31, 2020
Result type: Reports
Project Number: SR0638-000
Product Line: Common Drug Review

Generic Name: Halobetasol propionate and tazarotene

Brand Name: Duobrii

Manufacturer: Bausch Health, Canada Inc.

Indications: Psoriasis, moderate to severe plaque

Manufacturer Requested Reimbursement Criteria1: Improving the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis.

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openDecember 19, 2019
Call for patient input closedFebruary 14, 2020
Clarification:

- Patient input submission received from Canadian Psoriasis Network (CPN), Canadian Skin Patient Alliance (CSPA) and the Canadian Association of Psoriasis Patients (CAPP)

Submission receivedJanuary 24, 2020
Submission acceptedFebruary 07, 2020
Review initiatedFebruary 10, 2020
Draft CADTH review report(s) provided to sponsor for commentApril 24, 2020
Deadline for sponsors commentsMay 05, 2020
CADTH responses on draft review report(s) provided to sponsorJune 05, 2020
Expert committee meeting (initial)June 17, 2020
Draft recommendation issuedJune 30, 2020
End of embargo periodAugust 13, 2020
Clarification:

- Request for extension to embargo period received from the sponsor

- Embargo extension request granted

- Reconsideration requested

- Reconsideration request under assessment by CADTH